Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 Reports Declining Revenues, Increased Losses in Q2 of FY2004

NEW YORK, March 16 (GenomeWeb News) - Accelr8 Technology today reported growing losses and shrinking revenues for the second quarter of its fiscal year 2004.


The company booked $153,000 in revenues for the quarter, which ended Jan. 31, down from $202,000 during the same period a year ago.


R&D expenses stayed essentially flat at $138,000, compared to $136,000 during the same quarter last year.


Losses amounted to $372,000, or $.04 per share, up from $281,000, or $.03 per share, during the year-ago period.


The company did not state its cash or cash equivalents.


Accelr8, of Denver, also said that it expects Schott Nexterion to become the exclusive outsource manufacturer and marketer of its OptArray products this fall.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.